{"id":12108,"date":"2017-04-23T08:48:22","date_gmt":"2017-04-23T08:48:22","guid":{"rendered":"http:\/\/revoscience.com\/en\/?p=12108"},"modified":"2017-04-24T07:44:23","modified_gmt":"2017-04-24T07:44:23","slug":"study-demonstrates-efficacy-investigational-treatment-hcv-subgroup","status":"publish","type":"post","link":"https:\/\/www.revoscience.com\/en\/study-demonstrates-efficacy-investigational-treatment-hcv-subgroup\/","title":{"rendered":"Study Demonstrates Efficacy of Investigational Treatment in HCV Subgroup"},"content":{"rendered":"

\"\"Study results\u00a0demonstrate that the oral, once-daily treatment regimen of glecaprevir\/pibrentasvir (G\/P) resulted in 95% sustained virologic response rates at 12 weeks post treatment (SVR12) in patients with Hepatitis C virus (HCV) genotype 3. In the ENDURANCE-3 study, presented at The International Liver Congress\u2122 2017 in Amsterdam, The Netherlands, patients infected with HCV genotype 3 without cirrhosis and who had no previous treatment history were treated with the new regimen for eight or 12 weeks, which was well tolerated. G\/P had a similar safety profile to the commonly used combination of sofosbuvir and daclatasvir for 12 weeks, to which G\/P was actively compared in the study.<\/span><\/p>\n

Around 180 million people globally have chronic HCV infection,1 including approximately 15 million people in the EU.2 Genotype 3 patients have become the most difficult subgroup of patients to cure.3 Although there have been recent advances in direct-acting antiviral therapies for HCV genotype 1, genotype 3 remains a challenge and is a highly prevalent strain of the virus globally.<\/span><\/p>\n

“While there has been great progress made in the treatment of patients with Hepatitis C, there remain limited options for those with genotype 3 disease. As such, we are pleased to see that the investigational combination of glecaprevir\/pibrentasvir achieved high SVR12 rates, in treatment na\u00efve, non-cirrhotic patients,” said Dr Graham Foster, Queen Mary University of London, United Kingdom and lead study author. “Treatment with this once-daily regimen for eight weeks could provide a highly efficacious and well-tolerated option for treatment na\u00efve, non-cirrhotic patients with Hepatitis C, genotype 3, if approved by the regulatory authorities.”<\/span><\/p>\n

ENDURANCE-3 is a Phase 3, open-label, active-controlled study in which 348 treatment na\u00efve, non-cirrhotic HCV genotype 3 patients were randomised to receive 12 weeks of once-daily therapy with either co-formulated glecaprevir\/pibrentasvir, or with sofosbuvir plus daclatasvir. Subsequently, 157 patients were enrolled to receive glecaprevir\/pibrentasvir for eight weeks. The primary endpoint of the study was the percentage of patients who achieved SVR12.<\/span><\/p>\n

SVR12 was achieved in 222\/233 (95%) (95% confidence interval 93-98) of patients treated with glecaprevir\/pibrentasvir for 12 weeks, and in 111\/115 (97%) (95% confidence interval 91-99) of patients treated with sofosbuvir plus daclatasvir for 12 weeks. In patients treated with glecaprevir\/pibrentasvir for eight weeks, SVR12 was achieved in 149\/157 (95%) (95% confidence interval 92-98) of patients. Relapse occurred in 1% of patients in both 12 week treatment regimens, and in 3% of patients in the eight week regimen. Adverse events (71%) were mostly mild and there were no serious treatment-related adverse events.<\/span><\/p>\n

“These results are more than encouraging, considering that treatment options for HCV genotype 3 are still suboptimal,” said Prof Francesco Negro, Divisions of Gastroenterology and Hepatology of Clinical Pathology, University Hospital of Geneva, Switzerland, and EASL Governing Board Member.<\/span><\/p>\n

Source: dddmag<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Study results\u00a0demonstrate that the oral, once-daily treatment regimen of glecaprevir\/pibrentasvir (G\/P) resulted in 95% sustained virologic response rates at 12 weeks post treatment (SVR12) in patients with Hepatitis C virus (HCV) genotype 3. In the ENDURANCE-3 study, presented at The International Liver Congress\u2122 2017 in Amsterdam, The Netherlands, patients infected with HCV genotype 3 without […]<\/p>\n","protected":false},"author":6,"featured_media":12109,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16,26],"tags":[],"class_list":["post-12108","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biology","category-medicine"],"featured_image_urls":{"full":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2017\/04\/ddd1704_HCV.jpg",800,534,false],"thumbnail":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2017\/04\/ddd1704_HCV-150x150.jpg",150,150,true],"medium":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2017\/04\/ddd1704_HCV-300x200.jpg",300,200,true],"medium_large":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2017\/04\/ddd1704_HCV-768x513.jpg",750,501,true],"large":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2017\/04\/ddd1704_HCV.jpg",750,501,false],"1536x1536":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2017\/04\/ddd1704_HCV.jpg",800,534,false],"2048x2048":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2017\/04\/ddd1704_HCV.jpg",800,534,false],"ultp_layout_landscape_large":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2017\/04\/ddd1704_HCV.jpg",800,534,false],"ultp_layout_landscape":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2017\/04\/ddd1704_HCV.jpg",800,534,false],"ultp_layout_portrait":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2017\/04\/ddd1704_HCV.jpg",600,401,false],"ultp_layout_square":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2017\/04\/ddd1704_HCV.jpg",600,401,false],"newspaper-x-single-post":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2017\/04\/ddd1704_HCV.jpg",734,490,false],"newspaper-x-recent-post-big":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2017\/04\/ddd1704_HCV.jpg",539,360,false],"newspaper-x-recent-post-list-image":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2017\/04\/ddd1704_HCV.jpg",95,63,false],"web-stories-poster-portrait":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2017\/04\/ddd1704_HCV.jpg",640,427,false],"web-stories-publisher-logo":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2017\/04\/ddd1704_HCV.jpg",96,64,false],"web-stories-thumbnail":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2017\/04\/ddd1704_HCV.jpg",150,100,false]},"author_info":{"info":["Amrita Tuladhar"]},"category_info":"Biology<\/a> Medicine<\/a>","tag_info":"Medicine","comment_count":"0","_links":{"self":[{"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/posts\/12108","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/comments?post=12108"}],"version-history":[{"count":0,"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/posts\/12108\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/media\/12109"}],"wp:attachment":[{"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/media?parent=12108"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/categories?post=12108"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/tags?post=12108"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}